ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
A Novel, Highly Sensitive Quantitative Polymerase Chain Reaction Assay for the Diagnosis of Subarachnoid and Ventricular Neurocysticercosis and for Assessing Responses to Treatment.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00001205 (Natural History of Treated Neurocysticercosis and Long-Term Outcomes), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Natural History of Treated Neurocysticercosis and Long-Term Outcomes
Who cites it
28 citing papers in PubMed, 50 citations in OpenAlex.
- Effect of different management strategies on outcomes in subarachnoid neurocysticercosis: a descriptive, multicentre, retrospective cohort study in the USA.EClinicalMedicine · 2026Article
- Taenia solium neurocysticercosis: Its current epidemiological, diagnostic, therapeutic, and control landscapes.PLoS neglected tropical diseases · 2026Review
- Persistent MRI Abnormalities After Successful Treatment of Subarachnoid and Intraventricular Neurocysticercosis: A Case Series.Neurology. Clinical practice · 2025Article
- Eosinophil recruitment and activation in the central nervous system of patients with subarachnoid neurocysticercosis.Journal of neuroinflammation · 2025Article
- Molecular Mimicry Drives Locally Produced Autoantibodies in Subarachnoid Neurocysticercosis.Open forum infectious diseases · 2025Article
- Parasite contamination of soil in different Peruvian locations and outside built environments.Parasites & vectors · 2025Article
- Improved Nucleic Acid Amplification Test for the Diagnosis of Onchocerciasis and Its Use for Detection of Circulating Cell-free DNA.The Journal of infectious diseases · 2025Article
- Immunologic Profiling of CSF in Subarachnoid Neurocysticercosis Reveals Specific Interleukin-10-Producing Cell Populations During Treatment.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Concomitant Parenchymal, Subarachnoid, and Ventricular Neurocysticercosis in Rome, Italy: A Case Report with a 4-Year Follow-Up.Tropical medicine and infectious disease · 2024Article
- Subarachnoid Neurocysticercosis Case Series Reveals a Significant Delay in Diagnosis-Requiring a High Index of Suspicion Among Those at Risk.Open forum infectious diseases · 2024Article
- Massive neurocysticercosis in a ten-year-old girl: a case report.BMC pediatrics · 2024Article
- From laboratory to clinical practice: an update of the immunological and molecular tools for neurocysticercosis diagnosis.Frontiers in parasitology · 2024Review
- Insights into the diagnosis, vaccines, and control of Taenia solium, a zoonotic, neglected parasite.Parasites & vectors · 2023Review
- A Novel, Highly Sensitive Nucleic Acid Amplification Test Assay for the Diagnosis of Loiasis and its Use for Detection of Circulating Cell-Free DNA.The Journal of infectious diseases · 2023Article
- Metagenomic next-generation sequencing in the diagnosis of neurocysticercosis: A case report.World journal of clinical cases · 2023Article
- Triplex ELISA for Assessing Durability of Taenia solium Seropositivity after Neurocysticercosis Cure.Emerging infectious diseases · 2023Article
- Human Neurocysticercosis: An Overview.Pathogens (Basel, Switzerland) · 2022Review
- Update on the diagnosis and management of neurocysticercosis.Arquivos de neuro-psiquiatria · 2022Review
- A recombinant monoclonal-based Taenia antigen assay that reflects disease activity in extra-parenchymal neurocysticercosis.PLoS neglected tropical diseases · 2022Article
- Membrane Technology for Rapid Point-of-Care Diagnostics for Parasitic Neglected Tropical Diseases.Clinical microbiology reviews · 2021Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTreatment of subarachnoid neurocysticercosis (NCC) is complicated, and assays that can guide treatment are not widely available. The reproducibility and scalability of molecular-based biomarkers would be of great use.
methodsThe Taenia solium genome was mined and primers and probes were designed to target repeats with the highest coverage; the most sensitive, specific, and efficient repeat (TsolR13) was selected for clinical testing. We tested 46 plasma samples and 36 cerebral spinal fluid (CSF) samples taken from patients with subarachnoid or ventricular disease using quantitative polymerase chain reaction (qPCR).
resultsThe analytic sensitivity of TsolR13 was 97.3% at 240 attograms (ag) of T. solium genomic DNA and 100% analytic specificity. The clinical sensitivity in detecting active subarachnoid or ventricular disease in symptomatic patients was 100% in CSF and 81.3% in plasma. The predictive ability to distinguish active from cured disease was better for CSF (94.4% of those cured had negative qPCR results) than for plasma (86.7% of those cured tested negative). Some subjects also had plasma DNA detectable intermittently for years after being cured. Overall, the test performance was equivalent to T. solium antigen detection.
conclusionsA qPCR test for the detection of the highly repetitive Tsol13 sequence has been developed and shown to be highly sensitive and specific for NCC, but also useful as a test of cure in CSF and for the definitive diagnosis of NCC in plasma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.